Novo Nordisk · 1 day ago
Internship - Cardiovascular Marketing
Plainsboro, NJ, US
Internship
Onsite
InternNovo Nordisk is a global pharmaceutical company dedicated to creating lasting change for long-term health. The internship position involves supporting pre-launch activities for a cardiovascular therapeutic asset, coordinating marketing tactics, and contributing to market research and stakeholder communications.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Support pre‑launch activities for a cardiovascular therapeutic asset
Help coordinate creation and approval of digital marketing tactics
Liaise with internal teams and agencies to track assets and timelines
Assist with media planning and performance optimization
Contribute to market research and stakeholder communications
Participate in the program's capstone event, the Innovation in Action Case Competition
Work closely to develop an innovative and comprehensive solution to a business problem currently facing Novo Nordisk
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than April 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress graduate or doctoral degree in Business Administration, Pharmacy or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase